| New and emerging treatments for osteoporosis. | |
| | |
MedLine Citation:
|
PMID: 17551368 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: This review will focus on three new treatments for postmenopausal osteoporosis which have either been recently released (intravenous ibandronate), or have completed (zoledronic acid) or are currently in (denosumab) phase III trials. RECENT FINDINGS: A number of agents have demonstrated fracture risk reduction in randomized clinical trials, however, successful treatment of osteoporosis in the individual patient remains a challenge. Adherence to, and persistence with, all current osteoporosis medications are poor, being approximately 50% at 1 year for weekly bisphosphonates. Poor adherence to therapy makes it unlikely that the significant fracture reduction seen in clinical trials will be realized in clinical practice. SUMMARY: New therapies will not only have to demonstrate safety and efficacy, but also provide some advantage to patient persistence through either less frequent dosing schedules or elimination of gastrointestinal disturbances, the most common adverse effects encountered with bisphosphonates. This review will focus on three such agents that have either been recently released (intravenous ibandronate), or have completed (zoledronic acid) or are currently in (denosumab) phase III trials. |
| | |
Authors:
|
Michael Maricic |
Related Documents
:
|
8931608 - Assessing whether to perform a confirmatory randomized clinical trial. 22729988 - Prevalence and concurrence of anxiety, depression and fatigue over time in multiple scl... 22863358 - Is primary prevention of clostridium difficile infection possible with specific probiot... 9005138 - The benefits of participation in clinical trials. 17897478 - Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: ... 16959928 - Epidemiology of depression and antidepressant therapy after acute respiratory failure. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in rheumatology Volume: 19 ISSN: 1040-8711 ISO Abbreviation: Curr Opin Rheumatol Publication Date: 2007 Jul |
Date Detail:
|
Created Date: 2007-06-06 Completed Date: 2007-08-23 Revised Date: 2013-06-03 |
Medline Journal Info:
|
Nlm Unique ID: 9000851 Medline TA: Curr Opin Rheumatol Country: United States |
Other Details:
|
Languages: eng Pagination: 364-9 Citation Subset: IM |
Affiliation:
|
University of Arizona School of Medicine, Tucson, Arizona 85704, USA. mikemaricic@msn.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
adverse effects,
therapeutic use* Antibodies, Monoclonal, Humanized Bone Density / drug effects Bone Density Conservation Agents / adverse effects, therapeutic use* Clinical Trials, Phase III as Topic Diphosphonates / adverse effects, therapeutic use* Drug Administration Routes Drug Administration Schedule Female Humans Imidazoles / adverse effects, therapeutic use* Osteoporosis, Postmenopausal / drug therapy* Patient Compliance RANK Ligand |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 0/RANK Ligand; 114084-78-5/ibandronic acid; 118072-93-8/zoledronic acid; 4EQZ6YO2HI/denosumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiovascular risks in spondyloarthritides.
Next Document: An update on glucocorticoid-induced osteoporosis.